Loading...
XSTO
ONCO
Market cap122mUSD
Dec 05, Last price  
5.35SEK
1D
1.90%
1Q
11.46%
IPO
-87.23%
Name

Oncopeptides AB

Chart & Performance

D1W1MN
XSTO:ONCO chart
P/E
—
P/S
36.41
EPS
—
Div Yield, %
—
Shrs. gr., 5y
26.34%
Rev. gr., 5y
0.00%
Revenues
32m
-10.14%
0000000118,295,0008,355,00035,220,00031,648,000
Net income
-285m
L+14.25%
-33,093,978-53,341,000-114,445,869-247,620,000-419,449,000-740,705,000-1,594,693,000-1,430,318,000-337,951,000-249,111,000-284,607,000
CFO
-261m
L-6.77%
-31,438,604-52,808,000-104,262,104-271,497,000-333,727,000-690,566,000-1,296,509,000-1,516,391,000-420,509,000-279,493,000-260,570,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Oncopeptides AB (publ), a biotech company, develops pharmaceuticals drugs for the treatment of cancer in the United States, Europe, and internationally. Its lead product candidate is melflufen, an anti-cancer peptide drug conjugate for the treatment of relapsed refractory multiple myeloma in adult patients. Oncopeptides AB (publ) was incorporated in 2000 and is headquartered in Stockholm, Sweden.
URL
https://www.oncopeptides.se/
IPO date
Feb 22, 2017
Employees
63
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT